MedTrace Logo

Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer

NCT01026337 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 43

Last updated 2019-06-25

No results posted yet for this study

Summary

Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment.

Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.

Conditions

Interventions

GENETIC

mutation analysis

Correlative study

OTHER

pharmacological study

Correlative study

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Undergo DCE-MRI

DRUG

sunitinib malate

Given orally

OTHER

immunohistochemistry staining method

Correlative study

OTHER

laboratory biomarker analysis

Correlative study

Sponsors & Collaborators

  • Abramson Cancer Center at Penn Medicine

    lead OTHER

Principal Investigators

  • Stephen Keefe · Abramson Cancer Center at Penn Medicine

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30
Primary Completion
2015-12-31
Completion
2018-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01026337 on ClinicalTrials.gov